Shackelford Pharma
Growth Stage
PIONEERING FOR PATIENTS
Overview
Platform
Dealmaker Securities
Start Date
12/12/2022
Close Date
12/12/2023
Min. Goal
$1,500
Max. Goal
$12,520,000
Min. Investment
$1,500
Security Type
Equity - Common
Series
Series A
Funding Type
RegA+
Price Per Share
$1.50
Pre-Money Valuation
$68,195,651
Location
Vancouver, British Columbia
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
High
Shackelford Pharma is raising funds independently through Reg A+ crowdfunding with DealMaker Securities as the Broker-Dealer. It is a biopharmaceutical company dedicated to developing medicines for neurological diseases. The company is currently developing SP1707 as its first drug candidate as a long-acting cannabinoid formulation for patients suffering from seizures. Mark Godsy and Dr. Alan Shackelford founded Shackelford Pharma in 2018. The current crowdfunding campaign has a maximum target of $12.5 million. The campaign proceeds will be used for research and development and general working capital.
Balance Sheet
|
Cash and Cash Equivalents |
$6,143,513 |
|
Accounts and Notes Receivable |
$54,611 |
| Total Assets |
$6,411,228 |
|
Accounts Payable & Accrued Liabilities |
$403,212 |
|
Long Term Debt |
$0 |
|
Total Liabilities |
$6,411,228 |
|
Total Stockholders' Equity |
$6,008,016 |
| Total Liabilities and Equity |
$6,411,228 |
Statement of Comprehensive Income Information
|
Depreciation and Amortization |
$6,552 |
| Net Income |
$-3,520,134 |
|
Earnings Per Share - Basic |
$-0.09 |
|
Earnings Per Share - Diluted |
$-0.09 |
Auditor: Dale Matheson Carr-Hilton Labonte LLP
Financials as of: 12/12/2022
Create a free account today to gain access to KingsCrowd analytics.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.